8,903 results match your criteria Gynecologic Tumor Markers


Ferroptosis-Related Long Noncoding RNAs as Prognostic Biomarkers for Ovarian Cancer.

Front Oncol 2022 9;12:888699. Epub 2022 Jun 9.

Department of Traditional Chinese Gynecology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.

Ovarian cancer (OC) is a highly malignant gynecologic tumor with few treatments available and poor prognosis with the currently available diagnostic markers and interventions. More effective methods for diagnosis and treatment are urgently needed. Although the current evidence implicates ferroptosis in the development and therapeutic responses of various types of tumors, it is unclear to what extent ferroptosis affects OC. Read More

View Article and Full-Text PDF

Enhanced synergistic antitumor effect of a DNA vaccine with anticancer cytokine, MDA-7/IL-24, and immune checkpoint blockade.

Virol J 2022 Jun 25;19(1):106. Epub 2022 Jun 25.

Department of Influenza and Other Respiratory Viruses, Pasteur Institute of Iran, P.O. Box: 1316943551, Tehran, Iran.

Background: MDA-7/IL-24 cytokine has shown potent antitumor properties in various types of cancer without exerting any significant toxicity on healthy cells. It has also been proved to encompass pro-immune Th1 cytokine-like behavior. Several E7 DNA vaccines have developed against human papillomavirus (HPV)-related cervical cancer. Read More

View Article and Full-Text PDF

Randomized multicenter phase II trial of prophylactic irradiation of para-aortic lymph nodes in advanced cervical cancer according to tumor hypoxia: Korean Radiation Oncology Group (KROG 07-01) study.

Int J Cancer 2022 Jun 25. Epub 2022 Jun 25.

Research Institute and Hospital, National Cancer Center, Goyang, South Korea.

We conducted a prospective phase II study on whether extended-field irradiation (EFI) confers survival benefits depending on hypoxic markers in locally advanced uterine cervical cancer (LAUCC). RNA-seq was performed to identify immune and hypoxic gene signatures. A total of 288 patients were randomized to either EFI or pelvic radiotherapy (PRT). Read More

View Article and Full-Text PDF

Carcinoid ovary with synchronous carcinoid tumour of the appendix: report of a rare occurrence with review of literature.

BMJ Case Rep 2022 Jun 24;15(6). Epub 2022 Jun 24.

Gynaecologic Oncology, Dr B Borooah Cancer Society Trust, Guwahati, Assam, India.

Carcinoid tumours are present in a wide range of organs but most frequently involve the gastrointestinal tract and rarely reported in gynaecological organs. Literature reports that the prevalence of ovarian carcinoid is 0.3%-1% of ovarian neoplasms and accounts for only 5% of ovarian teratomas. Read More

View Article and Full-Text PDF

Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer.

Int J Gynecol Cancer 2022 Jun 24. Epub 2022 Jun 24.

City of Hope National Medical Center, Duarte, California, USA

Objective: Preclinical evidence and early clinical trials have demonstrated the activity of SPL-108, a targeted agent that inhibits CD44 mediated induction of multidrug resistance specifically to paclitaxel and platinum agents. We conducted a phase I, open label, dose escalation study of the safety and tolerability of the combination of SPL-108 with weekly paclitaxel in patients with platinum resistant CD44+ ovarian, primary peritoneal, or fallopian tube cancer.

Methods: Patients with platinum resistant histologically proven epithelial ovarian, primary peritoneal, or fallopian tube cancers and measurable disease according to RECIST (Response Evaluation Criteria in Solid Tumours) version 1. Read More

View Article and Full-Text PDF

Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy.

Pathol Res Pract 2022 Jun 18;236:153990. Epub 2022 Jun 18.

Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University. Beijing Maternal and Child Health Care Hospital, Beijing, China. Electronic address:

Background: Lymphocyte activation gene-3 (LAG-3) is a novel molecule that participates in the immune escape of tumor cells and is a target for immunotherapy. However, the expression of LAG-3 in patients with endometrial cancer (EC) has not been comprehensively characterized.

Objectives: We elucidated the expression of LAG-3 and investigated its correlation with clinicopathological parameters, ProMisE subtypes, CD8 T-cell infiltration and relapse-free survival (RFS) in a retrospective cohort of 421 patients with endometrial cancer. Read More

View Article and Full-Text PDF

CA-125 monitoring in gynecologic cancer patients with COVID-19: A case series.

Gynecol Oncol Rep 2022 Aug 17;42:101029. Epub 2022 Jun 17.

Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, United States.

CA-125 has long been utilized as a surveillance biomarker for gynecologic malignancies but can be elevated in other conditions, including infection. A study of tumor markers in non-cancer patients saw a rise in CA-125 values during severe COVID-19 infections. Given the potential confounding effect this could have on surveillance and treatment planning, we sought to describe the impact of COVID-19 on CA-125 trends in a gynecologic oncology patient population. Read More

View Article and Full-Text PDF

Exosomal MicroRNA as Biomarkers for Diagnosing or Monitoring the Progression of Ovarian Clear Cell Carcinoma: A Pilot Study.

Molecules 2022 Jun 20;27(12). Epub 2022 Jun 20.

Department of Bioscience and Laboratory Medicine, Hirosaki University Graduate School of Health Sciences, Hirosaki 036-8564, Japan.

Ovarian cancer is the most common cause of gynecological malignancy-related mortality since early-stage disease is difficult to diagnose. Advanced clear cell carcinoma of the ovary (CCCO) has dismal prognosis, and its incidence has been increasing in Japan, emphasizing the need for highly sensitive diagnostic and prognostic CCCO biomarkers. Exosomal microRNAs (miRNAs) secreted by tumor cells are known to play a role in carcinogenesis; however, their involvement in ovarian cancer is unclear. Read More

View Article and Full-Text PDF

Antioxidative, Anti-Inflammatory, Anti-Obesogenic, and Antidiabetic Properties of Tea Polyphenols-The Positive Impact of Regular Tea Consumption as an Element of Prophylaxis and Pharmacotherapy Support in Endometrial Cancer.

Int J Mol Sci 2022 Jun 16;23(12). Epub 2022 Jun 16.

Faculty of Medical Sciences and Health Sciences, Siedlce University of Natural Sciences and Humanities, Konarskiego 2, 08-110 Siedlce, Poland.

Endometrial cancer (EC) is second only to cervical carcinoma among the most commonly diagnosed malignant tumours of the female reproductive system. The available literature provides evidence for the involvement of 32 genes in the hereditary incidence of EC. The physiological markers of EC and coexisting diet-dependent maladies include antioxidative system disorders but also progressing inflammation; hence, the main forms of prophylaxis and pharmacotherapy ought to include a diet rich in substances aiding the organism's response to this type of disorder, with a particular focus on ones suitable for lifelong consumption. Read More

View Article and Full-Text PDF

A Laboratory-Friendly CTC Identification: Comparable Double-Immunocytochemistry with Triple-Immunofluorescence.

Cancers (Basel) 2022 Jun 10;14(12). Epub 2022 Jun 10.

Translational Oncology Laboratory, Avera Research Institute, Sioux Falls, SD 57105, USA.

The source of circulating tumor cells (CTC) in the peripheral blood of patients with solid tumors are from primary cancer, metastatic sites, and a disseminated tumor cell pool. As 90% of cancer-related deaths are caused by metastatic progression and/or resistance-associated treatment failure, the above fact justifies the undeniable predictive and prognostic value of identifying CTC in the bloodstream at stages of the disease progression and resistance to treatment. Yet enumeration of CTC remains far from a standard routine procedure either for post-surgery follow-ups or ongoing adjuvant therapy. Read More

View Article and Full-Text PDF

Mesonephric-like Adenocarcinoma of the Uterine Corpus: Comprehensive Analyses of Clinicopathological, Molecular, and Prognostic Characteristics With Retrospective Review of 237 Endometrial Carcinoma Cases.

Cancer Genomics Proteomics 2022 Jul-Aug;19(4):526-539

Department of Pathology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Republic of Korea;

Background/aim: Uterine mesonephric-like adenocarcinoma (MLA) is a rare malignant tumor of the female genital tract.

Patients And Methods: We reviewed 237 endometrial carcinoma cases and investigated the clinicopathological and molecular characteristics of uterine MLA.

Results: We found that 3. Read More

View Article and Full-Text PDF

Curcumin and resveratrol inhibit chemoresistance in cisplatin-resistant epithelial ovarian cancer cells via targeting P13K pathway.

Hum Exp Toxicol 2022 Jan-Dec;41:9603271221095929

Second Department of Gynecology, 91593Cancer Hospital of Xinjiang Uygur Autonomous Region (Affiliated Cancer Hospital of Xinjiang Medical University), China.

Background: The activation of the PI3K/AKT/mTOR pathway has been proved to be associated with survival as well as proliferation of various tumour cells in multiple cancer types, including epithelial ovarian cancer (EOC).

Purpose: Moreover, the activation of the PI3K/AKT/mTOR pathway is the key mechanism responsible for higher invasiveness and migratory capacities of ovarian cancer cells. Furthermore, PI3K is crucial for activation of the PI3K/AKT/mTOR pathway; therefore, its inhibition might be an effective strategy against cancer. Read More

View Article and Full-Text PDF

Extensive HPV Genotyping Reveals High Association between Multiple Infections and Cervical Lesions in Chinese Women.

Dis Markers 2022 10;2022:8130373. Epub 2022 Jun 10.

Department of Pathology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200090, China.

Objective: The relationship between human papillomavirus (HPV) and cervical lesions has been extensively elucidated, but infection with multiple genotypes is less investigated due to methodology limitations. In the current study, with a method of genotyping 21 HPVs in a routine cervical screening population, we aimed to investigate the prevalence and diversity of HPV infections in Chinese women and further evaluate the impact of multiple infections of HPV on cervical lesion progression.

Methods: Totally, 73,596 patients who underwent 21-genotype HPV testing from January 2018 to April 2019 were retrieved from the database of the Department of Pathology, Obstetrics and Gynecology Hospital of Fudan University. Read More

View Article and Full-Text PDF

Initiation and elongation factor co-expression correlates with recurrence and survival in epithelial ovarian cancer.

J Ovarian Res 2022 Jun 19;15(1):73. Epub 2022 Jun 19.

Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria.

High grade epithelial ovarian cancer (EOC) represents a diagnostic and therapeutic challenge due to its aggressive features and short recurrence free survival (RFS) after primary treatment. Novel targets to inform our understanding of the EOC carcinogenesis in the translational machinery can provide us with independent prognostic markers and provide drugable targets. We have identified candidate eukaryotic initiation factors (eIF) and eukaryotic elongation factors (eEF) in the translational machinery for differential expression in EOC through in-silico analysis. Read More

View Article and Full-Text PDF

Endometrial Cancer-Infiltrating Mesenchymal Stem Cells Exhibit Immunosuppressive Effects.

Cell Transplant 2022 Jan-Dec;31:9636897221104452

Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien.

Endometrial cancer is the most common gynecologic cancer with high heterogeneity. However, there are limited treatment options for advanced endometrial carcinoma. In recent years, immunotherapy has broadly been used for the treatment of various cancers. Read More

View Article and Full-Text PDF

KAZN as a diagnostic marker in ovarian cancer: a comprehensive analysis based on microarray, mRNA-sequencing, and methylation data.

BMC Cancer 2022 Jun 16;22(1):662. Epub 2022 Jun 16.

Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin, China.

Background: Ovarian cancer (OC) is among the deadliest malignancies in women and the lack of appropriate markers for early diagnosis leads to poor prognosis in most cases. Previous studies have shown that KAZN is involved in multiple biological processes during development, such as cell proliferation, differentiation, and apoptosis, so defects or aberrant expression of KAZN might cause queer cell behaviors such as malignancy. Here we evaluated the KAZN expression and methylation levels for possible use as an early diagnosis marker for OC. Read More

View Article and Full-Text PDF

RadBone: bone toxicity following pelvic radiotherapy - a prospective randomised controlled feasibility study evaluating a musculoskeletal health package in women with gynaecological cancers undergoing pelvic radiotherapy.

BMJ Open 2022 Jun 14;12(6):e056600. Epub 2022 Jun 14.

Department of Endocrinology, The Christie Hospital NHS Foundation Trust, Manchester, UK

Introduction: Patients receiving radiotherapy are at risk of developing radiotherapy-related insufficiency fractures, which are associated with increased morbidity and pose a significant burden to patients' quality of life and to the health system. Therefore, effective preventive techniques are urgently required. The RadBone randomised controlled trial (RCT) aims to determine the feasibility and acceptability of a musculoskeletal health package (MHP) intervention in women undergoing pelvic radiotherapy for gynaecological malignancies and to preliminary explore clinical effectiveness of the intervention. Read More

View Article and Full-Text PDF

High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells.

Nat Commun 2022 Jun 13;13(1):3385. Epub 2022 Jun 13.

School of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, USA.

Extremely rare circulating tumor cell (CTC) clusters are both increasingly appreciated as highly metastatic precursors and virtually unexplored. Technologies are primarily designed to detect single CTCs and often fail to account for the fragility of clusters or to leverage cluster-specific markers for higher sensitivity. Meanwhile, the few technologies targeting CTC clusters lack scalability. Read More

View Article and Full-Text PDF

P504S/alpha-methylacyl-CoA racemase, HNF1β and napsin A in morular metaplasia and clear cell carcinoma of the endometrium: An immunohistochemical analysis.

Pathol Res Pract 2022 May 27;236:153953. Epub 2022 May 27.

Gynecopathology and Breast Pathology Unit, Department of Woman and Child's Health Sciences and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Gynecologic Oncology Unit, Department of Woman and Child's Health Sciences and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Aims: Endometrial morular metaplasia (MorM) can show cytoplasm clarification, which may mimic clear cell carcinoma (CCC), especially on biopsy. We aimed to assess the expression of CCC markers in MorM.

Methods: Twenty cases of MorM with areas of cytoplasmic clarification were assessed by immunohistochemistry for HNF1β, Napsin A, and P504S/alpha-Methylacyl-CoA racemase (AMACR); 60 tumors were selected as controls (20 classical MorM, 20 conventional squamous differentiation and 20 CCC). Read More

View Article and Full-Text PDF

Efficacy and Side Effects of Irinotecan Combined with Nedaplatin versus Paclitaxel Combined with Cisplatin in Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer and Tumor Marker Analysis: Based on a Retrospective Analysis.

Comput Math Methods Med 2022 1;2022:5936773. Epub 2022 Jun 1.

Provincial Clinical College of Fujian Medical University (Department of Gynecology, Fujian Provincial Hospital), Fuzhou, 350001 Fujian, China.

Objective: A case-control study was adopted to investigate the efficacy and side effects of irinotecan combined with nedaplatin (NP) versus paclitaxel combined with cisplatin for locally advanced cervical cancer (CC) neoadjuvant chemotherapy (NACT) and to analyze the changes in tumor marker levels.

Methods: A total of 96 patients with locally advanced CC who were treated from October 2019 to October 2021 were enrolled in our hospital as the research subjects, and their clinical data were collected for retrospective analysis and grouped according to their treatment regimens. Among them, 53 patients received paclitaxel combined with cisplatin as the control group, and the other 43 patients received irinotecan combined with NP as the observation group. Read More

View Article and Full-Text PDF

Spirulina phycocyanin extract and its active components suppress epithelial-mesenchymal transition process in endometrial cancer via targeting TGF-beta1/SMAD4 signaling pathway.

Biomed Pharmacother 2022 Aug 9;152:113219. Epub 2022 Jun 9.

School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan; School of Food and Safety, Taipei Medical University, Taipei 11031, Taiwan; Nutrition Research Center, Taipei Medical University Hospital, Taipei 11031, Taiwan; Graduate Institute of Metabolism and Obesity Sciences, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan. Electronic address:

Metastasis is a major challenge in aggressive endometrial cancer treatment accounting for the high recurrence risk and poor prognosis of epithelial-mesenchymal transition (EMT), regulated by the transforming growth factor beta (TGFβ) signaling pathway, facilitates tumor metastasis. Spirulina phycocyanin extract (SPE) and its purified products allophycocyanin (APC) and C-phycocyanin (C-PC), derived from Spirulina platensis, can be considered a nutraceutical compound with the ability to inhibit tumor growth and metastasis. Current study aims to investigate the anti-metastatic potential of SPE, and its purified products APC, and C-PC on endometrial cancer both in vitro and in vivo. Read More

View Article and Full-Text PDF

VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients.

PLoS One 2022 10;17(6):e0269680. Epub 2022 Jun 10.

Department of Gynaecology and Gynaecologic Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.

Objective: At present, maintenance therapy with the antiangiogenic agent bevacizumab or with PARP-inhibitors represent two options for BRCA-wildtype ovarian cancer patients, after platinum-based first line chemotherapy. The identification of molecular markers to predict patient response to different maintenance therapies remains a major challenge. In the present study we analyzed the predictive potential of vascular endothelial growth factor C (VEGF-C) to identify ovarian cancer patients that might benefit from an antiangiogenic therapy. Read More

View Article and Full-Text PDF

The Role of Cancer-Associated Fibroblasts in Ovarian Cancer.

Cancers (Basel) 2022 May 26;14(11). Epub 2022 May 26.

Clinical Research Unit, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.

Ovarian cancer is a lethal gynecologic tumor and is generally resistant to conventional treatments. Stable cancer-associated fibroblasts (CAFs) are important cellular components in the ovarian cancer tumor microenvironment and may provide novel resources for future treatment strategies. Different subtypes of CAFs display specific functions in tumor pathogenesis and various CAF markers suggest potential treatment targets, such as FAP and GPR77. Read More

View Article and Full-Text PDF

Detection of ovarian cancer using plasma cell-free DNA methylomes.

Clin Epigenetics 2022 Jun 9;14(1):74. Epub 2022 Jun 9.

Sun Yat-Sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China.

Background: Ovarian cancer (OC) is a highly lethal gynecologic cancer, and it is hard to diagnose at an early stage. Clinically, there are no ovarian cancer-specific markers for early detection. Here, we demonstrate the use of cell-free DNA (cfDNA) methylomes to detect ovarian cancer, especially the early-stage OC. Read More

View Article and Full-Text PDF

Potential roles of claudin-3 and claudin-4 in ovarian cancer management.

J Egypt Natl Canc Inst 2022 Jun 6;34(1):24. Epub 2022 Jun 6.

Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, W12 0NN, UK.

Background: Ovarian cancer has the highest mortality amongst all gynaecological malignancies, with around two-thirds of patients diagnosed with advanced disease due to late presentation. Furthermore, around 90% of patients develop recurrence and eventually become chemoresistant. Therefore, there is a high demand to identify biomarkers specific to this disease for screening for early detection, as well as new therapeutic targets. Read More

View Article and Full-Text PDF

Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway.

Stem Cell Res Ther 2022 Jun 3;13(1):225. Epub 2022 Jun 3.

Department of Obstetrics and Gynecology, Keio University School of Medicine, 35, Shinanomachi, Shinjukuku, Tokyo, 160-8582, Japan.

Background: Distinct subsets of cancer stem cells (CSCs) drive the initiation and progression of malignant tumors via enhanced self-renewal and development of treatment/apoptosis resistance. Endometrial CSC-selective drugs have not been successfully developed because most endometrial cell lines do not contain a sufficient proportion of stable CSCs. Here, we aimed to identify endometrial CSC-containing cell lines and to search for endometrial CSC-selective drugs. Read More

View Article and Full-Text PDF

[Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors].

Zhonghua Fu Chan Ke Za Zhi 2022 May;57(5):352-360

Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing 100006, China.

To investigate the clinicopathological features, diagnosis, treatment and prognosis of simultaneous double primary gynecological malignant tumors. A total of 23 patients with simultaneous double primary malignant tumors of female reproductive system primarily treated in Beijing Obstetrics and Gynecology Hospital, Capital Medical University from January 1, 2010 to December 31, 2020 were retrospectively collected. The age, symptoms, tumor stage, tumor type, treatment and prognosis of patients were collected and followed up. Read More

View Article and Full-Text PDF

Cluster of differentiation frequency on antigen presenting-cells: The next step to cervical cancer prognosis?

Int Immunopharmacol 2022 Jul 28;108:108896. Epub 2022 May 28.

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Virology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address:

Viruses may transform infected cells into benign or malignant tumors, promoting cell growth and survival via various intracellular pathways. Some oncogenic DNA viruses, such as human papillomaviruses, can lead to squamous intraepithelial lesions and cervical cancer. Furthermore, the early HPV virus'soncoproteins have been attributed to cancer initiation and development and tumor-enhancing action. Read More

View Article and Full-Text PDF

Comprehensive Analysis of DNA Methylation and Transcriptome to Identify PD-1-Negative Prognostic Methylated Signature in Endometrial Carcinoma.

Dis Markers 2022 18;2022:3085289. Epub 2022 May 18.

Department of Radiology, The Third Xiangya Hospital, Central South University, 138 Tongzipo Road, Yuelu District, Changsha, China.

Background: Epigenetic mechanism plays an important role in endometrial carcinoma (EC). This study was designed to analyze the epigenetic mechanism between DNA methylation-driven genes (DEDGs) and drugs targeting DEDGs and to develop a DEDG score model for predicting the prognosis of EC.

Methods: Expression profile and methylation profile data of PD-1-negative EC samples were obtained from TCGA. Read More

View Article and Full-Text PDF

Metabolic Reprogramming and Lipophagy Mediates Survival of Ascites Derived Metastatic Ovarian Cancer Cells.

Asian Pac J Cancer Prev 2022 05 1;23(5):1699-1709. Epub 2022 May 1.

Department of Biochemistry, Kidwai Memorial Institute of Oncology Dr.M.H.Marigowda Road Bangalore, India.

Objective: The study was aimed at understanding the survival of metastatic ovarian cancer spheroids in the malignant ascites microenvironment.

Methods: All the assays were performed using aseptically collected patient samples. The cells were characterized for the expression of ovarian and cancer stem cell markers using immunocytochemistry. Read More

View Article and Full-Text PDF